1. Home
  2. INVX vs ZYME Comparison

INVX vs ZYME Comparison

Compare INVX & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INVX
  • ZYME
  • Stock Information
  • Founded
  • INVX 2024
  • ZYME 2003
  • Country
  • INVX United States
  • ZYME United States
  • Employees
  • INVX N/A
  • ZYME N/A
  • Industry
  • INVX
  • ZYME Biotechnology: Pharmaceutical Preparations
  • Sector
  • INVX
  • ZYME Health Care
  • Exchange
  • INVX NYSE
  • ZYME Nasdaq
  • Market Cap
  • INVX 954.4M
  • ZYME 956.0M
  • IPO Year
  • INVX N/A
  • ZYME 2017
  • Fundamental
  • Price
  • INVX $16.97
  • ZYME $14.35
  • Analyst Decision
  • INVX Sell
  • ZYME Buy
  • Analyst Count
  • INVX 1
  • ZYME 6
  • Target Price
  • INVX $15.00
  • ZYME $19.17
  • AVG Volume (30 Days)
  • INVX 577.2K
  • ZYME 544.8K
  • Earning Date
  • INVX 02-11-2025
  • ZYME 03-05-2025
  • Dividend Yield
  • INVX N/A
  • ZYME N/A
  • EPS Growth
  • INVX 175.29
  • ZYME N/A
  • EPS
  • INVX 6.87
  • ZYME N/A
  • Revenue
  • INVX $543,306,000.00
  • ZYME $62,199,000.00
  • Revenue This Year
  • INVX N/A
  • ZYME $21.53
  • Revenue Next Year
  • INVX $8.79
  • ZYME N/A
  • P/E Ratio
  • INVX $2.53
  • ZYME N/A
  • Revenue Growth
  • INVX N/A
  • ZYME N/A
  • 52 Week Low
  • INVX $12.54
  • ZYME $7.97
  • 52 Week High
  • INVX $25.19
  • ZYME $17.70
  • Technical
  • Relative Strength Index (RSI)
  • INVX N/A
  • ZYME 54.18
  • Support Level
  • INVX N/A
  • ZYME $13.58
  • Resistance Level
  • INVX N/A
  • ZYME $14.63
  • Average True Range (ATR)
  • INVX 0.00
  • ZYME 0.80
  • MACD
  • INVX 0.00
  • ZYME 0.02
  • Stochastic Oscillator
  • INVX 0.00
  • ZYME 38.77

About INVX INNOVEX INTERNATIONAL INC

Innovex International Inc designs, manufactures, and installs mission-critical drilling & deployment, well construction, completion, production, and fishing & intervention solutions to support upstream onshore and offshore activities worldwide. Its comprehensive portfolio extends throughout the lifecycle of the well; and innovative product integration ensures seamless transitions from one well phase to the next, driving efficiency, lowering cost, and reducing the rig site service footprint for the customer. With locations throughout North America, Latin America, Europe, the Middle East, and Asia, The team is readily available with technical expertise, conventional and innovative technologies, and ever-present customer service.

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Share on Social Networks: